MI SB1183

Beginning January 1, 2026, Michigan's Medicaid program must cover fertility diagnostic care, intrauterine insemination, ovulation-enhancing drugs, and related medical services for treating infertility, including at least 3 cycles of ovulation-enhancing medication per recipient's lifetime.

Coverage must be provided without discrimination based on age, ancestry, disability, domestic partner status, gender identity, genetic information, marital status, national origin, race, religion, sex, or sexual orientation.

Within 180 days of enactment, the Department of Health and Human Services must report to the legislature on whether in-vitro fertilization and standard fertility preservation services can be covered under Medicaid, possible methods for coverage under both fee-for-service and managed care, applicable waiver authorities, and required funding allocation.

Defines "infertility" to include recognized conditions causing loss of fertility, inability to establish pregnancy after 12 months of unprotected intercourse (or 6 months if age-related), inability to achieve pregnancy due to lack of necessary gametes, and increased risk of transmitting serious genetic abnormalities.

Defines covered services including fertility diagnostic care, intrauterine insemination, ovulation-enhancing drugs, and standard fertility preservation services such as gamete and embryo cryopreservation.